Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
Rhea-AI Summary
Agios Pharmaceuticals (NASDAQ: AGIO), a company focused on cellular metabolism and pyruvate kinase activation for rare diseases, has announced its upcoming participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for June 9, 2025, at 8:40 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A replay will remain available on the company's website for a minimum of two weeks after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – AGIO
In the trading session that priced this news, AGIO gained 2.09%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 8:40 a.m. ET.
The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
